Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
低剂量安罗替尼联合免疫检查点抑制剂可提高晚期非小细胞肺癌患者的生存率。
期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-022-03259-5
Yuan, Shumin; Peng, Ling; Liu, Yuqing; Till, Brian G; Yan, Xiang; Zhang, Jie; Zhu, Liping; Wang, Huijuan; Zhang, Shaokai; Li, Hongle; Gao, Quanli; Wang, Zibing